Quick Search

 

 


 

 

Home > Result Summaries: Compounds > ropinirole > Result Summary for 106207

Result Summary for 106207

Result Summary
Protocol ID: 106207
Clinical Study ID: 106207
Official Title: An open-label, multi-centre, observational, post-marketing surveillance to monitor the safety of REQUIP(ropinirole) administered in Korean restless leg syndrome patients according to the prescribing information
Phase: phase 4
Study Indications or Diseases:
  • Restless Legs Syndrome
Generic Name: ropinirole
Trade/Product Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL
Approved Drug Label: http://www.gsk.com/products.html
Results Summary: Click here to download result summary. Click here to download result summary.
Citations:
  • Ji-Yun Kim BA, Shin-Young Oh MS, Han-Kyu Lee MD, MS and Dr. Yil-Seob Lee MD, PhD. A Post-marketing Surveillance to Monitor the Safety of Ropinirole (Requip) in Korean Patients with Restless Legs Syndrome. [JPERM]. 2012;5:25-30.

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.